Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

ReHaptix

Financiado

Cerrado

Easy to use and highly accurate medical software for quantitative assessment of...

Easy to use and highly accurate medical software for quantitative assessment of impairments in neurologically injured people. Neurological disorders, caused by either stroke, multiple sclerosis (MS) or Parkinson’s diseases affect more than 30M people worldwide. Currently, Europe has the greatest percentage of population aged 65 or over (25%) and these nu... ver más

30/09/2019

ETH Zürich

71K€

Presupuesto del proyecto: 71K€

Líder del proyecto

EIDGENOESSISCHE TECHNISCHE HOCHSCHULE ZUERICH No se ha especificado una descripción o un objeto social para esta compañía.

Fecha límite participación Sin fecha límite de participación.

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2019-09-30

EIC-SMEInst-2018-2020: SME instrument

I+D

Cerrada hace 7 años

0% 70% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

1 Participantes

ETH Zürich

50.00K€ | Lider

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

INVESTIGACIÓN Y DESARROLLO EXPERIMENTAL DE UN... INVESTIGACIÓN Y DESARROLLO EXPERIMENTAL DE UNA NUEVA HERRAMI... 278K€ Cerrado

NUEVA TECNOLOGIA PARA EL TRATAMIENTO NEURORR... NUEVA TECNOLOGIA PARA EL TRATAMIENTO NEURORREHABILITADOR DE... 316K€ Cerrado

DPI2017-82694-R CONTERA INTELIGENTE PARA EL DIAGNOSTICO FUNCIONAL DE LA MARC... 58K€ Cerrado

PTQ-15-08078 DISEÑO Y DESARROLLO DE UNA HERRAMIENTA INFORMATICA DE EVALUA... 77K€ Cerrado

INNOGAIT Innovative Reflex based Gait Rehabilitation 71K€ Cerrado

CuPiD Closed loop system for personalized and at home rehabilitati... 3M€ Cerrado

Duración del proyecto: 7 meses Fecha Inicio: 2019-02-26
Fecha Fin: 2019-09-30

Líder del proyecto

EIDGENOESSISCHE TECHNISCHE HOCHSCHULE ZUERICH No se ha especificado una descripción o un objeto social para esta compañía.

Presupuesto del proyecto 71K€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Neurological disorders, caused by either stroke, multiple sclerosis (MS) or Parkinson’s diseases affect more than 30M people worldwide. Currently, Europe has the greatest percentage of population aged 65 or over (25%) and these numbers are expected to drastically grow (3% per year) increasing the population affected by these chronic conditions. Neurological rehabilitation is an expensive doctor-supervised program designed for treating these diseases. However, there is currently no effective assessment to objectively measure and monitor the rehabilitation progress. Current solutions for performing assessments do not provide clinical evidences of their validity, show lack of accuracy and are limited to one disease type. ReHaptix has developed a medical software, designed for remote quantitative assessment of impairments in neurologically injured people. ReHaptix has developed 9 tests so far, of which 4 have been clinically validated (the gold standard), and 5 are currently under clinical validation. Healthcare Professionals (HCPs) can use the ReHaptix tests to evaluate their patients in the hospital, rehabilitation clinic or private practice, or patients can perform the tests autonomously at home on a touchscreen tablet, which empowers them about their recovery. Furthermore, patients can remotely share their results with their HCPs, who can adapt the treatment and medication, or schedule medical appointment and home-setting assessments as required. During the feasibility assessment, a go-to-market strategy and a supply chain will be established, as well as further development plan will be drafted. During the second phase of innovation project, ReHaptix will optimize the software increasing the number of tests and developing a functional mHealth app. Clinical trials will then be initiated to obtain the CE mark as a medical device.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores